MYX presentation at Jefferies Healthcare Conference
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA TO PRESENT AT THE JEFFERIES
HEALTHCARE CONFERENCE IN NEW YORK CITY
09 June 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that
Shawn Patrick O’Brien, Chief Executive Officer, and Aaron Gray, Chief Financial Officer of Mayne
Pharma, will present at the Jefferies Healthcare Conference in New York City as follows:
Date:
Time:
Webcast:
Friday, June 9, 2023
11:00am US Eastern Time
Click here
A copy of the presentation slides is attached.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
US:
Lisa M. Wilson
+917 543 9932
ir@maynepharma.com
Authorised for release to the ASX by the Chair.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma
also provides contract development and manufacturing services to clients worldwide. Mayne
Pharma has a 40- year track record of innovation and success in developing new oral drug delivery
systems. These technologies have been successfully commercialised in numerous products that
continue to be marketed around the world. To learn more about Mayne Pharma, please visit
maynepharma.com.
Mayne Pharma
Group Limited
ASX:MYX
Jefferies Global Healthcare Conference
June 9, 2023
Shawn Patrick O’Brien, CEO
Aaron Gray, CFO
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited
Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Non-IFRS information
● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements.
Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items
are considered by the Directors to provide a meaningful basis for comparison from period to period.
● Earnings before interest, tax, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the
operating earnings and performance of the Group and this information may be useful for investors.
● The non-IFRS financial information has not been audited by the Group’s auditors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and
contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as
‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or
implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially
from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under
the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The
factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory
regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major
customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research
collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investorrelations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● ANNOVERA®, ABSORICA®, ACTIKERALL®, ACZONE®, BIJUVA®, EPIDUO® FORTE, IMVEXXY®, NEXTSTELLIS®, ORACEA® and VITAMED® are trademarks of third
parties.
2
Mayne Pharma at a Glance
Specialty Pharmaceutical Company Focused on U.S. Women’s Health & Dermatology
Putting the right people, products, and processes in place to address the needs of patients and
drive long-term sustainable growth in each of our three segments.
U.S. Women’s Health
Dermatology
With TXMD acquisition in Dec 2022,
Mayne Pharma became one of top 2
women’s health companies in the U.S.
1 in 3 U.S. Rx can be filled by Mayne Pharma
• Proprietary brands
(FABIOR®, SORILUX®, DORYX®, LEXETTE®)
•
Reproductive Health
•
•
Flagship product
NEXTSTELLIS®
ANNOVERA® and
vitaMedMD® acquired
December 2022
Speciality brands
(Cosette, Upsher-Smith, Torrent,
GALDERMA, Sandoz, Encube)
Patients
International
•
CDMO – Salisbury, Australia
Menopause Management
•
Australian Products
•
•
International Products
BIJUVA® and IMVEXXY®
acquired December 2022
Process
3
Mayne Pharma Ecosystem
Unique mix of capabilities, including drug sourcing, pharmacy network, and sales access
DRUG SOURCING
PHARMACY NETWORK
CUSTOMER COVERAGE
• Strong Rx portfolio covering 1/3
of dermatology prescriptions
and ~85% of contraceptives(1)
• Adelaide Apothecary for cashpay claims, licensed to operate
in 50 states
• Access to wholesalers and
intermediary platforms
• 400+ specialty pharmacy
locations and partnerships for
reimbursed claims
• 130+ territory representatives
well-positioned to execute
within Dermatology and
Women’s Health
• Established relationships
with Bx & Gx manufacturers
• Reaching 50k+ prescribers in
targeted therapeutic areas,
covering >60% of prescribing
activity
• Access to channels serving a
younger, female demographic
1. IQVIA recent 12 month TRx totals by molecule
4
How We Got Here
7 months of significant structural change resetting Mayne Pharma for profitable growth
● New U.S.
focused
leadership
team
● Organisational
focus on U.S.
women’s health
and dermatology
Patients
Process
● Strategies to
maximise
potential of
International
PROFITABLE
GROWTH
● Right-sizing of cost structure
● Balance Sheet reset
● Reduction of complexity
● Increased transparency
5
How We Got Here
Shifting focus to U.S. Women’s Health and Dermatology
Major Investment
in U.S. Women’s
Health
Sale of Metrics
Contract Services
Oct
2022
➢US$475MM
➢16.5x EBITDA
Nov
2022
Dec
2022
➢Commercialization
rights for TXMD’S
women’s health
assets
➢US$140MM up front
➢3.8x EBITDA
Sale of U.S.
Retail Generics
to Dr. Reddy’s
Jan
2023
Feb
2023
Mar
2023
Apr
2023
➢US$90MM up front
+ up to US$15MM
in milestone
payments
MAYNE PHARMA BECOMES A LEADER
IN WOMEN’S HEALTHCARE IN THE U.S.
6
Focused, strategic transition to core product platforms
Women’s Health
(Branded Products)
Dermatology
(Portfolio Products)
Current state
● Top 2 women’s health platform in U.S.
● Flagship product NEXTSTELLIS® launched July ‘21,
rapidly ramping now
● 100 person sales force
● Target positive earnings 2H23
●
●
●
●
Future state
● Leading platform in Women’s health with strong
margins
● Platform for additional accretive product
acquisitions, leveraging infrastructure
● Sustainable contribution margins across the portfolio
● Differentiated channel strategy
● Addition of new products to drive growth
● US$ 13.6M
● US$ 49.3M
● US$ 86.8M
● US$ 60M
LTM Revenues
Portfolio of 20 products covering range of conditions
National sales team of 43 people
Positive net revenue and contribution margin
Improving momentum following channel inventory issues
H2 FY22, H1 FY23
Revenue @ runrate(1)
(1) WH Run rate = 4 weeks 05/05 – 05/26 * 12 months, Derm run rate Jan – April monthly average * 12 months
7
1H23 Financial Highlights
– do not reflect the go forward business
A$million1
1H23
1H22
1H23 v 1H22
Reported Revenue
101.2
150.4
(33%)
Reported Gross Profit
7.9
64.6
(88%)
Reported EBITDA
(99.2)
66.1
(250%)
Reported Net Loss After Tax
(129.2)
(208.4)
(38%)
Underlying EBITDA2
(53.1)
63.5
(184%)
Underlying EBITDA (excl. NEXTSTELLIS®)3
(25.9)
72.2
(136%)
● Financial results are presented from continuing operations to exclude MCS which was disposed of on 4 October 2022
● Group Revenue down largely as a result of decline in Portfolio Products Division (PPD) where sales declined in retail generics as a result of
continued competition , and a decline in revenue in certain products in the dermatology business as the normalisation of inventories in the
distribution channel impacted sales for much of the half
● Reported Gross Profit and EBITDA affected by foreign exchange losses on hedges placed against receipt of MCS proceeds
● Reported net loss after tax driven by deferred tax asset write-downs and intangible asset impairments
1. Attributable to members. EBITDA excludes asset impairments.
2. Refer to FY22 Results Presentation for adjustments to underlying EBITDA
3. Excludes NEXTSTELLIS® direct contribution (gross profit less direct marketing / set up costs)
8
Revenue Highlights (A$MM)
$28.6
$48.0
1HFY23*
Branded Products/Women’s Health
• Portfolio delivering steady revenue growth
and positive contribution in 2H23
Portfolio Products/Dermatology
$13.4
$11.2
$6.3
• Delivering positive net revenue and
contribution margin
$26.8
$75.5
2HFY22
$50.0
Portfolio Products/Retail Generics
• Sold to Dr. Reddy’s in April ‘23 for US$90MM up
front + up to US$15MM in milestone payments
OVERALL MAYNE PHARMA
$4.2
$27.6
$76.9
$41.7
1HFY22
• Positive revenue and contribution margin in 2H23
• Return to Group profitability in FY24
Portfolio Products (Retail Generics)
Portfolio Products (Derm.)
Branded Products (Women's Health)
International
* Adjustment to dermatology co-pay
accrual method resulted in overstatement
in FY22, and an adjustment made to
reduce revenue in 1HFY23
9
Capital Management Plan
➢ Divestitures of non-strategic business units put Mayne Pharma in strong cash position
- MCS (US$475MM)
- U.S. Retail Generics (US$90MM up front + up to US$15MM milestone payments)
REPAID
A$359MM in
syndicated debt
facilities
PAID A$47MM
special dividend
(Jan 2023)
WOUND DOWN
receivablesbased revolver
Announced
BUY BACK of up
to 10% of issued
capital
Current CASH
position of
A$239MM(1)
RGx expected to generate tax loss
carryforwards of up to US $100M
1. Net cash position of A$135.8MM (cash less Rubric Convertible note, current balance of receivables financing facility)
10
Branded Products Division (BPD):
Our Women’s Health Franchise
Women’s Health: Strategic Rationale
A highly attractive market that offers attractive organic and inorganic growth opportunities
Attractive
market
fundamentals
• Estimated US patient population:
- 20mm women use short-acting and long-acting prescription contraceptives
- 32mm menopausal women have symptomatic VVA
• US contraceptive market valued at US$7.9B(1)
• US menopause market valued at US$2.0B(2)
• Favourable regulatory settings support increased access and affordability to
contraceptive coverage
Portfolio of
differentiated
products with
IP protection
• Complimentary branded product portfolio across the large and growing reproductive
health and menopause markets
• National sales team of 100 reps and sales managers provide specialist coverage to
generalist and specialist HCPs
• Significant sales and financial leverage across existing sales infrastructure
1. Grandview Research. U.S. Contraceptive Market Size, Share & Trends Analysis Report, 2022-2030
2. IQVIA, MAT Sales
12
Women’s Health Acquisition: Accelerating Our Vision to Become a Leader
Acquired Portfolio
Reproductive Health
Menopause Management
13
Building a Leading U.S. Women’s Health Business
NEW SALES & MARKETING INFRASTRUCTURE
● Increased sales team from 86 → 100 to better reach target customers
● Refreshed team training initiative to improve sales productivity and impact
● Implemented full marketing mix to drive awareness and usage, including Direct to Consumer (DTC)
campaigns
ACQUISITION OF WOMEN’S HEALTH PORTFOLIO
●
●
●
●
Resulted in Mayne Pharma becoming a leader in U.S. Women’s Health
Portfolio already delivering positive cash and earnings
Planned launch of lower strength BIJUVA® in 2HFY24
Q3-FY23 net sales exceeded, prior calendar Q4-2023 reported sales
CONTINUING TO DRIVE NEXTSTELLIS® GROWTH
●
●
●
●
Increased call activity
DTC campaign driving 900% YoY increase in monthly consumer visitation to Nextstellis.com
Monthly cycle count increased to 26,596 in March 2023 (+27% from Dec 2022)
March NRx up 20% over February, and NEXTSTELLIS® Weekly Cycles now over 7,000
NRx totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 31Mar23
NRx totals based on IQVIA Rapid Weekly adjusted for non-reporting pharmacies through 28Apr23
14
Branded Products Division (BPD) Financial Results
NEXTSTELLIS®
A$million
1H23
2H22
1H22
● 1HFY23 NEXTSTELLIS® revenues were
US$7.1MM
Reported revenue
13.4
6.3
4.2
Reported Gross
Profit
10.7
5.1
3.3
Gross Profit %
80%
81%
79%
Direct operating
expense1
36.2
29.1
25.7
Direct contribution
(25.5)
(24.0)
(22.5)
- Up 123% on 2HFY22 (US$3.2m)
- Up 567% on 1HFY22 (US$1.1m)
TOLSURA® (SUBA®-itraconazole) and SOLTAMOX®
(tamoxifen)
● 1HFY23 TOLSURA® and SOLTAMOX® revenues of
$1.9MM increased 35% on 2HFY22
1. Direct marketing and NEXTSTELLIS® set up costs
15
Branded Products Division (BPD)/U.S. Women’s Health
STRATEGIC PRIORITIES
➢ Successfully implement new commercial strategy for NEXTSTELLIS® to
accelerate growth in the US and Australia
➢ Deliver on the full Women’s Health franchise
➢ Improve margins and provide better patient access
➢ Broaden portfolio with complementary products that leverage current
infrastructure
16
Portfolio Products Division (PPD):
Dermatology & Retail Generics
Dermatology: Strategic Rationale
A highly attractive market that offers attractive organic and inorganic growth opportunities
Attractive
market
fundamentals
• U.S. Dermatology is estimated to be ~ US$10B with a forecasted annual growth rate of
7%-9% over the coming decade
- Ageing population, rising incidence of skin diseases, growing awareness, and
increased spend on personal care
• Acne is the most common skin condition and affects ~ 50 million Americans annually
• Increasing preference for consultation with specialist dermatologists for chronic skin
conditions supports continued innovation and growth
Portfolio of
differentiated
products with
IP protection
• Complementary branded (DORYX®, SORILUX®, LEXETTE® and FABIOR®) and generic
portfolio of 20 products covering a range of dermatological conditions
• One in every three current U.S. prescriptions can be filled by Mayne Pharma
• National sales team of 43 people providing expert coverage to the specialist
dermatological HCP segment
18
Building Leadership in the the U.S. Dermatology Market
Specialty Partners
Proprietary Brands
19
Portfolio Products Division (PPD)/Dermatology
Building on strength of market position
CONTINUED MOMENTUM
● Improving momentum following 1H-FY23 channel inventory issues which resulted in recalibration of
pricing, GTN and lower volumes in some products
● Seeing positive impact of new product launches
- DORYX® MPC 60 (Feb 2023)
- gORACEA® (March 2023)
● Pricing and sales cadence has stabilised across key products
● Return to positive contribution margin during 3Q-FY23
CLOSELY MANAGING PORTFOLIO
● Actively managing each brand to maximise sustainable contribution margins
● Further development of differentiated channel strategy for patient access
● Looking to add new products to drive profitable growth
20
Portfolio Products Division (PPD) Financial Results
Dermatology
● Revenue and contribution materially
impacted by inventory work through
following 2HFY22 sales activities
- New market entrants affected key
products
- Significant inventories in distribution
channel led to sales discounting and
GTN adjustments to maintain customers
A$million
1H23
2H22
1H22
Reported revenue
59.1
125.6
118.6
Reported Gross
Profit
(12.7)
26.5
52.6
Gross Profit %
-21%
21%
44.3%
Direct operating
expense1
20.5
17.5
15.4
Direct contribution
(33.2)
9.0
37.2
Retail generics
● Division sold to Dr. Reddy’s Laboratories in
April 2023
1. Direct marketing costs
21
Portfolio Products Division (PPD)/Dermatology
STRATEGIC PRIORITIES
➢ Build on strength of market position with strong, profitable pipeline of
new products to meet broader patient needs
➢ Strengthen contribution margin through channel discipline and effective
management of new launches and appropriate channel supply
agreements
➢ Maintain market presence as top 10 US products by revenue gABSORICA® (isotretinoin) capsules, gEPIDUO® FORTE (adapalene/benzoyl
peroxide) gel and gACZONE® (dapsone) gel
➢ Execute differentiated channel strategy through specialty pharmacy
growth and online platforms like GoodRx
22
International
International
Continue profitable growth of International and CDMO business
ACT ON ORGANISATIONAL DESIGN REVIEW
● Manufacturing improvements/implementation of lean practices underway to enable capacity increase,
supply reliability, and cost efficiency
● Ongoing reduction of waste and deliberate focus on productivity
FOCUSED REVENUE GROWTH
● New business development capability implemented to secure new local customers and open new market
opportunities
● Implementing best in class processes and metrics to drive efficient sales execution
● Continue to leverage contract development and manufacturing as a differentiator and growth stream
24
Accelerating International Growth and Profitability
NEXTSTELLIS® launch in Australia
Federal Government grant to modernise Salisbury
● High Speed
Encapsulator
● High Speed Blister
Packing Line with
Serialisation
capabilities
Continue growth of Australian based CDMO business
● >10,000 interactions with healthcare providers since
launch in August 2022
● >10,000 samples distributed to physician offices
● Double digit CDMO
revenue growth vs 2HFY22
● Active promotion as a full
service CDMO with oral
solid dose and semi-solid
capabilities in ‘tier 1’
markets
25
International
A$million
1H23
2H22
1H22
Reported revenue
27.6
26.8
27.6
- OST approved in Switzerland
Reported Gross
Profit
8.9
8.8
8.8
- Submitted in Austria
Gross Profit %
33%
33%
32%
Direct operating
expense1
6.1
4.9
4.7
Direct
contribution
2.8
3.9
4.1
● KAPANOL® /KADIAN® (morphine) market expansion to treat
Opioid Substitution Therapy (OST);
● KAPANOL® /KADIAN® (morphine) regional expansion for pain
indication in China
- Tripartite agreement signed and clinical trial application
submitted in China
● Australian dermatology portfolio extended through launch of
ACTIKERALL® (fluorouracil and salicylic acid for treatment of
actinic keratosis)
● Trading relationships and cadence with Dr Reddy's being
established with some sales expected later in current half
● NEXTSTELLIS® oral contraceptive launched in Australia
10%
CDMO
A$27.6m
51%
Australian products
39%
International products
Share of International revenue by type 1H-FY23
1. Direct marketing costs and general administration expenses including finance, HR and IT
26
Outlook
Strategic Priorities for FY23 & FY24
Driving shareholder value
# 1 Priority:
Accelerate NEXTSTELLIS®
growth to profitability
Deliver full profit
potential of
Women’s Health
Improve Margins
& Access
Acquire
Accretive Assets
Accelerate
AU Growth
Successfully
Successfully
Deliver on the full
commercialise
implement
new
Women’s Health
NEXTSTELLIS® in
commercial
franchise
the
strategy
forUS and
ANNOVERA®
Australia
NEXTSTELLIS®
to
BIJUVA®
accelerate growth
IMVEXXY®
in the US and
NEXTSTELLIS®
Australia
Pre-Natal Vitamins
US channel
strategy to
improve margins
in dermatology
and women’s
health and
provide better
patient access
Broaden portfolio
with
complementary
products that
leverage existing
commercial
infrastructure in
dermatology and
women’s health
Continued
profitable growth
of Australian based
specialty
pharmaceutical,
International sales
and CDMO
business
28
Outlook
➢ Significant business transition in FY23 with the completion of the sale of MCS and Retail Generics and
the acquisition of the TXMD portfolio
➢ Momentum continues to build across BPD/Women’s Health portfolio following acquisition and
investment in new products as well as our sales and marketing capability
- Anticipated timing for NEXTSTELLIS® to achieve its breakeven 1H24
- Portfolio is delivering steady revenue growth and positive contribution in 2H23 with the acquired assets more
than offsetting NEXTSTELLIS® investments for growth
➢ Dermatology has returned to delivering positive net revenue and contribution margin
- Momentum is anticipated to continue through 2H23, supported by the recent product launches
➢ Relatively flat performance for International in 2H23 while operational excellence plan is implemented
➢ Overall business expected to deliver positive revenue and contribution margin in 2H23 vs 1H23
- Return to Company profitability in FY24
➢ Continuation of capital management plan
29
Q&A
Mayne Pharma
Group Limited
ASX:MYX
You deserve tomorrow.
30
Share your feedback
Discover